Skip to main content Accessibility help
×
Home

Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice

  • Chen-Dong Wang (a1), Bao-Song Teng (a1), Yan-Ming He (a2), Jia-Sheng Wu (a3), Deng Pan (a1), Luan-Feng Pan (a4), Dan Zhang (a2), Zhao-Hua Fan (a2), Hong-Jie Yang (a2) and Ping Zhou (a1)...

Abstract

Protein tyrosine phosphatase 1B (PTP1B) is implicated in the negative regulation of the insulin signalling pathway by dephosphorylating the insulin receptor (IR) and IR substrates. Ganodermalucidum has traditionally been used for the treatment of diabetes in Chinese medicine; however, its anti-diabetic potency and mechanism in vivo is still unclear. Our previously published study reported a novel proteoglycan PTP1B inhibitor, named Fudan-Yueyang-Ganoderma lucidum (FYGL) from G. lucidum, with a half-maximal inhibitory concentration (IC50) value of 5·12 (sem 0·05) μg/ml, a protein:polyglycan ratio of 17:77 and 78 % glucose in polysaccharide, and dominant amino acid residues of aspartic acid, glycine, glutamic acid, alanine, serine and threonine in protein. FYGL is capable of decreasing plasma glucose in streptozotocin-induced diabetic mice with a high safety of median lethal dose (LD50) of 6 g/kg. In the present study, C57BL/6 db/db diabetic mice were trialed further using FYGL as well as metformin for comparison. Oral treatment with FYGL in db/db diabetic mice for 4 weeks significantly (P < 0·01 or 0·05) decreased the fasting plasma glucose level, serum insulin concentration and the homeostasis model assessment of insulin resistance. FYGL also controlled the biochemistry indices relative to type 2 diabetes-accompanied lipidaemic disorders. Pharmacology research suggests that FYGL decreases the plasma glucose level by the mechanism of inhibiting PTP1B expression and activity, consequently, regulating the tyrosine phosphorylation level of the IR β-subunit and the level of hepatic glycogen, thus resulting in the improvement of insulin sensitivity. Therefore, FYGL is promising as an insulin sensitiser for the therapy of type 2 diabetes and accompanied dyslipidaemia.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice
      Available formats
      ×

Copyright

Corresponding author

*Corresponding authors: P. Zhou, fax +86 21 55664038, email pingzhou@fudan.edu.cn and H.-J. Yang, email yanghongjie1964@yahoo.com.cn

References

Hide All
1Harris, M & Zimmet, P (1997) Classification of diabetes mellitus and other categories of glucose intolerance. In International Textbook of Diabetes Mellitus, 2nd ed., pp. 923 [, editors]. Chichester: John Wiley and Sons Limited.
2Barr, AJ, Ugochukwu, E, Lee, WH, et al. (2009) Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 136, 352363.
3Valentino, L & Pierre, J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71, 713721.
4Tonks, NK, Diltz, CD & Fischer, EH (1988) Purification of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem 263, 67226730.
5Goldstein, BJ (2002) Protein-tyrosine phosphatase 1B (PTP1B): emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocr Metab 87, 24742480.
6Seely, BL, Staubs, PA, Reichart, DR, et al. (1996) Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 45, 13791385.
7Zabolotny, JM, Haj, FG, Kim, YB, et al. (2004) Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action. J Biol Chem 279, 2484424851.
8Cromlish, WA, Tang, M, Kyskan, R, et al. (2006) PTP1B-dependent insulin receptor phosphorylation/residency in the endocytic recycling compartment of CHO-IR cells. Biochem Pharmacol 72, 12791292.
9Asante-Appiah, E & Kennedy, BP (2003) Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol Endocrinol Metab 284, E663E670.
10Saltiel, AR (1996) Diverse signaling pathways in the cellular actions of insulin. Am J Physiol Endocrinol Metab 270, E375E385.
11Ahmad, F, Azevedo, JJ, Cortright, R, et al. (1997) Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest 100, 449458.
12Elchebly, M, Payette, P, Michaliszyn, E, et al. (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 15441548.
13Escriva, F, Rodriguez, AG, Millan, EF, et al. (2010) PTP1B deficiency enhances liver growth during suckling by increasing the expression of insulin-like growth factor-I. J Cell Physiol 225, 214222.
14Van Huijsduijnen, RH, Bombrun, A & Swinnen, D (2002) Selecting protein tyrosine phosphatases as drug targets. Drug Discov Today 7, 10131019.
15Park, H, Bhattarai, BR, Ham, SW, et al. (2009) Structure-based virtual screening approach to identify novel classes of PTP1B inhibitors. Eur J Med Chem 44, 32803284.
16Combs, AP (2010) Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 53, 23332344.
17Wasser, SP & Weis, AL (1999) Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 19, 6596.
18Wasser, SP (2011) Current findings, future trends, and unsolved problems in studies of medicinal mushrooms. Appl Microbiol Biotechnol 89, 13231332.
19Seto, SW, Lam, TY, Tam, HL, et al. (2009) Novel hypoglycemic effects of Ganoderma lucidum water-extracct in obese/diabetic (+ db/+db) mice. Phytomedicine 16, 426436.
20Meng, GL, Zhu, HY, Yang, SL, et al. (2011) Attenuating effects of Ganoderma lucidum polysaccharides on myocardial collagen cross-linking relates to advanced glycation end product and antioxidant enzymes in high-fat-diet and streptozotocin-induced diabetic rats. Carbohydr Polym 84, 180185.
21Yang, BK, Jeong, SC, Park, JB, et al. (2001) Swimming endurance capacity of mice after administration of exo-polymer produced from submerged mycelia culture of Ganoderma lucidum. J Microbiol Biotechn 11, 902905.
22Hikino, H & Mizuno, T (1989) Hypoglycemic actions of some heteroglycans of Ganoderma lucidum fruit bodies. Planta Med 55, 385385.
23Wachtel-Galor, S, Tomlinson, B & Benzie, IFF (2004) Ganoderma lucidum (‘Lingzhi’), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. Brit J Nutr 91, 263269.
24Teng, BS, Wang, CD, Yang, HJ, et al. (2011) A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice. J Agr Food Chem 59, 64926500.
25Kobayashi, K, Forte, TM, Taniguchi, S, et al. (2000) The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49, 2231.
26Kodama, H, Fujita, M & Yamaguchi, I (1994) Development of hyperglycaemia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice. Diabetologia 37, 739744.
27Folch, J, Lees, M & Sloane Stanley, GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226, 497509.
28Chernoff, J, Schievella, AR, Jost, CA, et al. (1990) Cloning of a cDNA for a major human protein-tyrosine-phosphatase. Proc Natl Acad Sci U S A 87, 27352739.
29Bialy, L & Waldmann, H (2005) Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew Chen Int Ed Engl 44, 38143839.
30Seiner, DR, Labutti, JN & Gates, KS (2007) Kinetics and mechanism of protein tyrosine phosphatase 1B inactivation by acrolein. Chem Res Toxicol 20, 13151320.
31Liu, DG, Gao, Y, Voigt, JH, et al. (2003) Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bond water of hydration. Bioorg Med Chem Lett 13, 30053007.
32Liu, GX, Tan, JZ, Niu, CY, et al. (2006) Molecular dynamics stimulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor. Acta Pharmacol Sin 27, 100110.
33Asante-Appiah, E, Patel, S, Dufresne, C, et al. (2002) The structure of PTP1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates. Biochemistry 41, 90439051.
34Bartlett, AH & Park, PW (2010) Proteoglycans in host–pathogen interactions: molecular mechanism and therapeutic implications. Exp Rev Mol Med 12, 122.
35Bach-Knudsen, KE & Jørgensen, H (2007) Impact of wheat and oat polysaccharides provided as rolls on the digestion and absorption processes in the small intestine of pigs. J Sci Food Agr 87, 23992408.
36Liu, G, Xin, ZL, Liang, H, et al. (2003) Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J Med Chem 46, 34373440.
37Glover, NR & Tracey, AS (1999) Modeling studies of the interaction between the insulin receptor kinase domain and protein tyrosine phosphatase 1B. J Am Chem Soc 121, 35793589.
38Glover, NR & Tracey, AS (1999) Nuclear magnetic resonance and restrained molecular dynamics studies of the interaction of an epidermal growth factor-derived peptide with protein tyrosine phosphatase 1B. Biochemistry 38, 52565271.
39Tagami, S, Sakaue, S, Honda, T, et al. (2002) Effects of troglitazone on skeletal muscle and liver protein tyrosine phosphatase activity in insulin-resistant Otsuka Long-Evans Tokushima fatty rats. Curr Ther Res 63, 572586.
40Tagami, S, Honda, T, Yoshimura, H, et al. (2002) Triglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima fatty rats. Tohoku J Exp Med 197, 169181.
41Haj, F, Zabolotny, JM, Kim, Y, et al. (2006) Liver-specific protein tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B− / − mice. J Biol Chem 280, 1503815046.
42Fukuda, S, Ohta, T, Sakata, S, et al. (2010) Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551. Diabetes Obes Metab 12, 299306.
43Wang, ZQ, Ribnicky, D, Zhang, XH, et al. (2011) An extract of Artemisia dracunculus L. enhances insulin receptor signaling and modulates gene expression in skeletal muscle in KK-Ay mice. J Nutr Biochem 22, 7178.
44Mao, XQ, Yu, F, Wang, N, et al. (2009) Hypoglycemic effect of polysaccharide enriched extract of Astragalus membranaceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism. Phytomedicine 16, 416425.
45Wu, Y, Ou-Yang, JP, Wu, K, et al. (2005) Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B. Acta Pharmacol Sin 26, 345352.
46Bosch, F, Pujol, A & Valera, A (1998) Transgenic mice in the analysis of metabolic regulation. Annu Rev Nutr 18, 207232.
47Kim, MK, Chae, YN, Son, MH, et al. (2008) PAR-5359, a well-banlanced PPARα/β dual agonist, exhibits equivalent antidiabetic and hypolidemic activities in vitro and in vivo. Eur J Pharmacol 595, 119125.
48Bhavsar, SK, Singh, S, Giri, S, et al. (2009) Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression. J Ethnopharmacol 124, 426433.
49Matveyenko, AV, Dry, S, Cox, HI, et al. (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes interactions with metformin. Diabetes 58, 16041615.
50Bhattarai, BR, Ko, JH, Shrestha, S, et al. (2007) Inhibition of IKK-β: a new development in the mechanism of the anti-obesity effects of PTP1B inhibitors SA18 and SA32. Bioorg Med Chem 20, 10751077.
51Garber, AJ (2002) Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabetes Obes Metab 4, S5S12.
52Tao, R, Ye, F, He, YB, et al. (2009) Improvement of high-fat-diet-induced metabolic syndrome by a compound from Balanophora polyandra Griff in mice. Eur J Pharmacol 616, 328333.
53Yamabe, N, Noh, JS, Park, CH, et al. (2010) Evaluation of lognan, iridoid glycoside from Corni fructus, on hepatic and renal glucolipotoxicity and inflammation in type 2 diabetic db/db mice. Eur J Pharmacol 648, 179187.
54Gum, RJ, Gaede, LL, Koterski, SL, et al. (2003) Redution of protein phosphatase 1B increase insulin-dependent signaling in ob/ob mice. Diabetes 52, 2128.

Keywords

Related content

Powered by UNSILO

Effect of a novel proteoglycan PTP1B inhibitor from Ganoderma lucidum on the amelioration of hyperglycaemia and dyslipidaemia in db/db mice

  • Chen-Dong Wang (a1), Bao-Song Teng (a1), Yan-Ming He (a2), Jia-Sheng Wu (a3), Deng Pan (a1), Luan-Feng Pan (a4), Dan Zhang (a2), Zhao-Hua Fan (a2), Hong-Jie Yang (a2) and Ping Zhou (a1)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.